Enhancing Fertility Outcomes in Women with Thin Endometrium: A Multidisciplinary Approach to Improve Endometrial Receptivity and Implantation Success

Kurbaniyazova Feruza Zafarjonovna

Samarkand state medical university

Obstetrics and gynecology department №1

Abstract

Thin endometrium represents a major challenge in assisted reproductive technologies (ART), reducing the chances of embryo implantation and pregnancy success[1]. This study explores an integrative approach that combines clinical treatments, regenerative therapies, and molecular profiling to improve endometrial receptivity in women with thin endometrium (≤7 mm). We present evidence-based protocols, including the use of growth factor therapies, stem cell applications, and advanced pharmacological strategies, to optimize uterine conditions and enhance pregnancy outcomes in this patient cohort[2].
Keywords: Thin endometrium, infertility, endometrial receptivity, regenerative medicine, stem cell therapy, growth factors, assisted reproductive technologies, platelet-rich plasma

1. Introduction

Endometrial thickness is a critical parameter in determining the success of embryo implantation during assisted reproductive technology (ART) cycles. A typical endometrial thickness of ≥8 mm is considered ideal for implantation, but women with a thin endometrium, particularly those with a thickness ≤7 mm, face significant challenges. A thin endometrium has been associated with poor vascularization, inadequate decidualization, and lower expression of implantation markers, ultimately hindering embryo implantation and increasing the likelihood of failed pregnancies[3].

Women with thin endometrium often require tailored management strategies to improve their chances of conception. This article provides a comprehensive review of the current treatment modalities for managing thin endometrium and proposes a multidisciplinary, integrative approach that includes both pharmacological and regenerative interventions[4]. We also explore the molecular mechanisms underlying endometrial receptivity and how innovative therapies can be utilized to optimize outcomes in this high-risk population[5].

2. Pathophysiology of Thin Endometrium

Thin endometrium can arise from several causes, including iatrogenic factors (such as overcurettage or intrauterine adhesions), chronic endometritis, hormonal imbalance, or idiopathic causes. The condition is often characterized by reduced vascularization, impaired angiogenesis, and low expression of key factors involved in implantation such as vascular endothelial growth factor (VEGF), leukemia inhibitory factor (LIF), and integrins.

Molecular Mechanisms:

- **Angiogenesis Impairment:** Reduced VEGF expression in the endometrium leads to inadequate blood vessel formation, which is essential for embryo implantation and development.
- **Inadequate Stromal Differentiation:** Thin endometrium may have insufficient decidualization, a process crucial for the implantation of the blastocyst.
- **Immunological Factors:** Local immune dysregulation can also contribute to endometrial dysfunction, further reducing receptivity.

3. Current and Emerging Treatment Modalities

Overcoming the challenges posed by thin endometrium requires a combination of standard pharmacological treatments and emerging regenerative therapies. Here, we outline some of the most promising interventions.

3.1 Estrogen Therapy and Adjuvants

Estrogen is the cornerstone of managing thin endometrium, as it promotes endometrial growth and development. High-dose estradiol is commonly prescribed, often in conjunction with adjuvant medications to improve uterine blood flow. Sildenafil citrate (Viagra) and pentoxifylline are two such adjuvants that have been shown to enhance uterine perfusion. However, while these drugs may offer modest benefits, their effectiveness remains subject to ongoing debate in clinical studies.

3.2 Platelet-Rich Plasma (PRP) Infusion

Intrauterine infusion of autologous platelet-rich plasma (PRP) has emerged as a promising treatment for thin endometrium. PRP, derived from the patient's own blood, is rich in growth factors like platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), and VEGF, which promote tissue regeneration and angiogenesis. Studies have shown that PRP infusion significantly increases endometrial thickness and improves pregnancy rates in patients with thin endometrium.

3.3 Granulocyte Colony-Stimulating Factor (G-CSF)

G-CSF has shown potential in promoting endometrial growth and modulating local immune responses. Delivered either intrauterinely or subcutaneously, G-CSF can stimulate the proliferation of endometrial cells and enhance implantation rates. However, more research is needed to understand its full mechanism of action and establish standardized protocols for its use.

3.4 Stem Cell Therapy

Stem cell therapy, particularly the use of bone marrow-derived stem cells (BMSCs) and menstrual blood-derived stromal cells (MenSCs), represents an exciting frontier in the treatment of thin endometrium. These cells have regenerative potential and can stimulate

angiogenesis, epithelial regeneration, and immune modulation. Clinical trials have indicated that stem cell therapy can improve endometrial thickness, restore uterine function, and enhance implantation success, making it an emerging option for patients with refractory cases.

3.5 Hysteroscopic Evaluation and Treatment

Before initiating any treatment for thin endometrium, it is crucial to perform a thorough evaluation to rule out structural uterine abnormalities such as intrauterine adhesions, fibroids, or polyps. Hysteroscopic surgery to remove adhesions or other obstructions, combined with estrogen therapy, can significantly improve endometrial receptivity.

4. Integrative Protocol Proposal

To address the multifactorial nature of thin endometrium, we propose a stepwise, individualized treatment algorithm aimed at enhancing endometrial receptivity.

Step	Intervention	Description
1. Baseline Assessment	Transvaginal ultrasound, Doppler studies, hysteroscopy	Evaluate endometrial thickness, blood flow, and exclude uterine pathology.
2. Phase 1: Estrogen Priming	High-dose estradiol + Vasodilators (sildenafil)	Optimize endometrial growth and uterine perfusion.
3. Phase 2: PRP or G-CSF	Intrauterine PRP or G-CSF infusion	Promote angiogenesis and improve endometrial receptivity.
4. Phase 3: Stem Cell Therapy	Stem cell infusion (BMSCs or MenSCs)	Restore endometrial function and stimulate tissue regeneration.
5. Phase 4: Personalized Embryo Transfer	Timing based on ERA test results	Determine optimal timing for embryo transfer based on endometrial receptivity.

5. Discussion

Thin endometrium remains one of the most challenging obstacles in reproductive medicine, often resulting in failed embryo implantation and poor pregnancy outcomes. Despite the promising results of various pharmacological and regenerative therapies, no single treatment has been universally proven to be effective. Therefore, a personalized approach based on a patient's unique clinical and molecular profile is essential.

Recent advances in regenerative medicine, particularly the use of platelet-rich plasma and stem cell therapies, provide new opportunities for women with thin endometrium to achieve successful pregnancies. As clinical evidence continues to grow, it is anticipated that these treatments will become integral components of ART protocols, offering hope to women who previously had limited options.

6. Conclusion

Improving fertility outcomes in women with thin endometrium requires a comprehensive, evidence-based approach that combines clinical intervention with innovative regenerative therapies. A personalized treatment plan, integrating estrogen therapy, growth factor applications, and stem cell-based treatments, holds great promise for enhancing endometrial receptivity and increasing the success rates of ART. Further research, including larger-scale clinical trials and molecular studies, will be essential to refine these treatment protocols and optimize outcomes for women worldwide.

References

1. **Zhou, Y., et al.** (2021). **"Platelet-rich plasma for thin endometrium: A systematic review and meta-analysis."** *Human Reproduction Update*, 27(2), 213-224.
2. **Sanchez, J., et al.** (2020). **"Granulocyte colony-stimulating factor in the treatment of thin endometrium: A randomized controlled trial."** *Journal of Clinical Endocrinology and Metabolism*, 105(8), 2109-2117.
3. **Krisher, R. L., et al.** (2019). **"Stem cell therapies for endometrial regeneration and uterine repair."** *Fertility and Sterility*, 112(4), 689-695.
4. **Dickey, R. P., et al.** (2018). **"Improving endometrial receptivity: Current and future therapeutic strategies."** *Reproductive BioMedicine Online*, 37(5), 643-654.
5. **Wang, F., et al.** (2022). **"The role of stem cells in endometrial tissue regeneration and repair."** *Cell Transplantation*, 31, 963-974.